• Krishna J Rocha-Singh and Janiece Trokey.
• Prairie Heart Institute, St. John's Hospital and Prairie Education and Research Cooperative, Department of Cardiology, Southern Illinois University School of Medicine, Springfield, Illinois 62794, USA. ksingh@prairieheart.com
• Catheter Cardiovasc Interv. 2002 Apr 1; 55 (4): 457-60.

AbstractThis feasibility study evaluated the therapeutic potential of combined GP IIb/IIIa receptor inhibition with abciximab and low-dose fibrinolysis with reteplase for treatment of acute femoropopliteal thrombosis. The simultaneous intra-arterial administration of abciximab in conjunction with low-dose reteplase (< or = 0.5 U/hr) was safe in 13 patients; 2 patients experienced major hemorrhagic complication at a reteplase dose of 1 U/hr. The primary success rate was 100%; all patients experienced an excellent clinical response with no clinical evidence of distal embolization. No patient required repeat endovascular or surgical revascularization during mean follow-up of 9.3 months. This promising new thrombolytic strategy for the treatment of peripheral arterial occlusive disease requires further study.Copyright 2002 Wiley-Liss, Inc.

42 keywords...

hide…